Eli Lilly and Company (NYSE:LLY) versus Prestige Consumer Healthcare (NYSE:PBH) Head-To-Head Comparison

Prestige Consumer Healthcare (NYSE:PBH) and Eli Lilly and Company (NYSE:LLY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Dividends

Prestige Consumer Healthcare pays an annual dividend of $1.90 per share and has a dividend yield of 4.2%. Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.6%. Prestige Consumer Healthcare pays out 53.2% of its earnings in the form of a dividend. Eli Lilly and Company pays out 23.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and Company has raised its dividend for 11 consecutive years.

Profitability

This table compares Prestige Consumer Healthcare and Eli Lilly and Company’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Eli Lilly and Company	33.53%	97.83%	23.23%

Earnings and Valuation

This table compares Prestige Consumer Healthcare and Eli Lilly and Company”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.10 billion	1.93	$190.30 million	$3.57	12.58
Eli Lilly and Company	$79.67 billion	13.62	$20.64 billion	$29.80	38.68

Eli Lilly and Company has higher revenue and earnings than Prestige Consumer Healthcare. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Prestige Consumer Healthcare has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Prestige Consumer Healthcare and Eli Lilly and Company, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1	3	2	0	2.17
Eli Lilly and Company	1	3	25	1	2.87

Prestige Consumer Healthcare presently has a consensus target price of $70.75, suggesting a potential upside of 57.51%. Eli Lilly and Company has a consensus target price of $1,305.25, suggesting a potential upside of 13.24%. Given Prestige Consumer Healthcare’s higher possible upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Eli Lilly and Company.

Insider and Institutional Ownership

99.9% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Eli Lilly and Company beats Prestige Consumer Healthcare on 14 of the 18 factors compared between the two stocks.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.